Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Congenital, familial and genetic disorders – page 20

  • 796 clinical trials
  • 308 recruiting
  • 374 conditions
  • 27 countries

Conditions in this area

374 conditions with trials, the busiest first

Duchenne muscular dystrophy28Factor VIII deficiency25Sickle cell disease25Cystic fibrosis24Hereditary angioedema22Spinal muscular atrophy17Hypertrophic cardiomyopathy16Type IIa hyperlipidaemia15Glycogen storage disease type II14Factor IX deficiency13Sickle cell anaemia13Congenital cystic kidney disease12Huntington's disease12Myotonic dystrophy12Non-small cell lung cancer12Osteochondrodysplasia12Adrenogenital syndrome11Alpha-1 antitrypsin deficiency11K-ras gene mutation11Retinitis pigmentosa11Severe myoclonic epilepsy of infancy11Thalassaemia11Fabry's disease10Hereditary angioedema with C1 esterase inhibitor deficiency10+350

Clinical trials in Congenital, familial and genetic disorders

796 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

796 clinical trials

Cardiac amyloidosis+1

Recruiting

Long-Term Safety Study of NTLA-2001 for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy or Transthyretin Amyloidosis-Related Cardiomyopathy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ziclumeran
  • Sponsor:Intellia Therapeutics Inc.

Factor IX deficiency

Recruiting

Study on the Safety and Effectiveness of REGV131 and LNP1265 for Adults with Hemophilia B

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adeno-Associated Virus Vector Serotype 8 Containing The Human F9 Gene
  • Sponsor:Regeneron Pharmaceuticals Inc.

Epidermolysis bullosa

Recruiting

Study on Diacerein 1% Ointment for Treating Generalized Epidermolysis Bullosa Simplex in Patients Aged 6 Months and Older

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Diacerein
  • Sponsor:Twi Biotechnology Inc.

Congenital cystic kidney disease

Recruiting

Study on the Safety and Effects of Tolvaptan for Children with Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Tolvaptan
  • Sponsor:Otsuka Pharmaceutical Development & Commercialization Inc.

VEXAS syndrome

Recruiting

Study of Azacitidine Treatment in Patients with VEXAS Syndrome

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Region Hovedstaden

Primary hyperoxaluria

Recruiting

Study on Stiripentol for Patients Aged 6 and Older with Primary Hyperoxaluria Types 1, 2, or 3

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Stiripentol
  • Sponsor:Biocodex

Sickle cell anaemia+1

Recruiting

Long-term Safety Study of Exagamglogene Autotemcel for Patients with Sickle Cell Disease or Transfusion-Dependent Thalassemia

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Exagamglogene Autotemcel
  • Sponsor:Vertex Pharmaceuticals Inc.

Huntington's disease

Recruiting

Study on the Use of Thiamine and Biotin for Patients with Huntington's Disease

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Biotin
  • Sponsor:Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla

Andersen-Tawil syndrome+1

Recruiting

Study of flecainide alone or with beta-blockers or calcium channel blockers and quinidine for treating ventricular arrhythmias in patients with Andersen-Tawil syndrome and MEPPC

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Atenolol
  • Sponsor:Amsterdam UMC Stichting

Congenital ectodermal dysplasia

Recruiting

Study on ER004 for Treating Boys with X-linked Hypohidrotic Ectodermal Dysplasia (XLHED)

InvestigationalNo placebo
Countries:FranceFrance
  • Substances:Human Immunoglobulin G1 Constant Region - Human Ectodysplasin-A1 Receptor-Binding Domain Fusion Protein
  • Sponsor:Fondation EspeRare

Retinitis pigmentosa

Recruiting

Study on the Safety and Effects of ISTEM-01 and Mycophenolate Mofetil for Patients with Retinitis Pigmentosa Due to a Genetic Mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Istem-01
  • Sponsor:Centre D'Etude Des Cellules Souches

Thalassaemia beta+2

Recruiting

Study of SP-420 for Patients with Transfusion-Dependent Alpha or Beta Thalassemia

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:(S)-4,5-Dihydro-2-[2-Hydroxy-4-(3,6-Dioxaheptyloxy)Phenyl]-4-Methyl-4-Thiazolecarboxylic Acid
  • Sponsor:Pharmacosmos A/S

Substances studied in this area

The therapies tested most often in Congenital, familial and genetic disorders trials.

Sirolimus21 clinical trialsSodium Chloride21 clinical trialsPrednisolone12 clinical trialsPlerixafor11 clinical trialsBusulfan10 clinical trialsIvacaftor9 clinical trialsMitapivat9 clinical trialsParacetamol8 clinical trialsTezacaftor8 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.